These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 33132643)

  • 1. Tacrolimus and mycophenolate mofetil as second-line treatment in autoimmune hepatitis: Is the evidence of sufficient quality to develop recommendations?
    Abdollahi M; Ekrami NK; Ghojazadeh M; Boezen HM; Somi M; Alizadeh BZ
    World J Gastroenterol; 2020 Oct; 26(38):5896-5910. PubMed ID: 33132643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis.
    Efe C; Hagström H; Ytting H; Bhanji RA; Müller NF; Wang Q; Purnak T; Muratori L; Werner M; Marschall HU; Muratori P; Gunşar F; Klintman D; Parés A; Heurgué-Berlot A; Schiano TD; Cengiz M; May-Sien Tana M; Ma X; Montano-Loza AJ; Berg T; Verma S; Larsen FS; Ozaslan E; Heneghan MA; Yoshida EM; Wahlin S
    Clin Gastroenterol Hepatol; 2017 Dec; 15(12):1950-1956.e1. PubMed ID: 28603052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic review with meta-analysis: mycophenolate mofetil as a second-line therapy for autoimmune hepatitis.
    Santiago P; Schwartz I; Tamariz L; Levy C
    Aliment Pharmacol Ther; 2019 Apr; 49(7):830-839. PubMed ID: 30761563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis.
    Efe C; Taii HA; Ytting H; Aehling N; Bhanji RA; Hagström H; Purnak T; Muratori L; Werner M; Muratori P; Klintman D; Schiano TD; Montano-Loza AJ; Berg T; Larsen FS; Alkhouri N; Ozaslan E; Heneghan MA; Yoshida EM; Wahlin S
    Dig Dis Sci; 2018 May; 63(5):1348-1354. PubMed ID: 29569003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open-label randomised-controlled trial of azathioprine vs. mycophenolate mofetil for the induction of remission in treatment-naive autoimmune hepatitis.
    Snijders RJALM; Stoelinga AEC; Gevers TJG; Pape S; Biewenga M; Tushuizen ME; Verdonk RC; de Jonge HJM; Vrolijk JM; Bakker SF; Vanwolleghem T; de Boer YS; Baven Pronk MAMC; Beuers U; van der Meer AJ; Gerven NMFV; Sijtsma MGM; van Eijck BC; van IJzendoorn MC; van Herwaarden M; van den Brand FF; Korkmaz KS; van den Berg AP; Guichelaar MMJ; Levens AD; van Hoek B; Drenth JPH;
    J Hepatol; 2024 Apr; 80(4):576-585. PubMed ID: 38101756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-line Agents in Pediatric Patients With Autoimmune Hepatitis: A Systematic Review and Meta-analysis.
    Zizzo AN; Valentino PL; Shah PS; Kamath BM
    J Pediatr Gastroenterol Nutr; 2017 Jul; 65(1):6-15. PubMed ID: 28644343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tacrolimus versus mycophenolate for AutoImmune hepatitis patients with incompLete response On first-line therapy (TAILOR study): a study protocol for a phase III, open-label, multicentre, randomised controlled trial.
    Stoelinga AEC; Tushuizen ME; van den Hout WB; Girondo MDMR; de Vries ES; Levens AD; Moes DAR; Gevers TJG; van der Meer S; Brouwer HT; de Jonge HJM; de Boer YS; Beuers UHW; van der Meer AJ; van den Berg AP; Guichelaar MMJ; Drenth JPH; van Hoek B;
    Trials; 2024 Jan; 25(1):61. PubMed ID: 38233878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the efficacy and safety of mycophenolate mofetil versus azathioprine in patients with autoimmune hepatitis (CAMARO trial): study protocol for a randomised controlled trial.
    Snijders RJALM; Stoelinga AEC; Gevers TJG; Pape S; Biewenga M; Verdonk RC; de Jonge HJM; Vrolijk JM; Bakker SF; Vanwolleghem T; de Boer YS; Pronk MAMCB; Beuers UHW; van der Meer AJ; van Gerven NMF; Sijtsma MGM; Verwer BJ; Gisbertz IAM; Bartelink M; van den Brand FF; Sebib Korkmaz K; van den Berg AP; Guichelaar MMJ; Soufidi K; Levens AD; van Hoek B; Drenth JPH;
    Trials; 2022 Dec; 23(1):1012. PubMed ID: 36514163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Mycophenolate Mofetil in Patients With Autoimmune Hepatitis and Suboptimal Outcomes After Standard Therapy.
    Roberts SK; Lim R; Strasser S; Nicoll A; Gazzola A; Mitchell J; Siow W; Khoo T; Hamarneh Z; Weltman M; Gow P; Janko N; Tse E; Mishra G; Cheng EH; Levy M; Cheng W; Sood S; Skoien R; Mitchell J; Zekry A; George J; MacQuillan G; Wigg A; Stuart K; Sievert W; McCaughan G;
    Clin Gastroenterol Hepatol; 2018 Feb; 16(2):268-277. PubMed ID: 29050991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcome of patients with difficult-to-treat autoimmune hepatitis receiving mycophenolate mofetil.
    Liberal R; Gaspar R; Lopes S; Macedo G
    Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101487. PubMed ID: 32651078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycophenolate mofetil as second line therapy in autoimmune hepatitis?
    Hennes EM; Oo YH; Schramm C; Denzer U; Buggisch P; Wiegard C; Kanzler S; Schuchmann M; Boecher W; Galle PR; Adams DH; Lohse AW
    Am J Gastroenterol; 2008 Dec; 103(12):3063-70. PubMed ID: 18853972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus.
    Chatur N; Ramji A; Bain VG; Ma MM; Marotta PJ; Ghent CN; Lilly LB; Heathcote EJ; Deschenes M; Lee SS; Steinbrecher UP; Yoshida EM
    Liver Int; 2005 Aug; 25(4):723-7. PubMed ID: 15998421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycophenolate mofetil for autoimmune hepatitis: a single practice experience.
    Wolf DC; Bojito L; Facciuto M; Lebovics E
    Dig Dis Sci; 2009 Nov; 54(11):2519-22. PubMed ID: 19082888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycophenolate mofetil as an alternative treatment for autoimmune hepatitis.
    Park SW; Um SH; Lee HA; Kim SH; Sim Y; Yim SY; Seo YS; Ryu HS
    Clin Mol Hepatol; 2016 Jun; 22(2):281-5. PubMed ID: 27246353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients.
    Zachou K; Gatselis N; Papadamou G; Rigopoulou EI; Dalekos GN
    J Hepatol; 2011 Sep; 55(3):636-646. PubMed ID: 21238519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoimmune hepatitis: Current and future therapeutic options.
    Doycheva I; Watt KD; Gulamhusein AF
    Liver Int; 2019 Jun; 39(6):1002-1013. PubMed ID: 30716203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis.
    Hlivko JT; Shiffman ML; Stravitz RT; Luketic VA; Sanyal AJ; Fuchs M; Sterling RK
    Clin Gastroenterol Hepatol; 2008 Sep; 6(9):1036-40. PubMed ID: 18586559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of mycophenolate mofetil for the treatment of autoimmune hepatitis-an observational study.
    Jothimani D; Cramp ME; Cross TJ
    J Clin Exp Hepatol; 2014 Sep; 4(3):221-5. PubMed ID: 25755564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy.
    Inductivo-Yu I; Adams A; Gish RG; Wakil A; Bzowej NH; Frederick RT; Bonacini M
    Clin Gastroenterol Hepatol; 2007 Jul; 5(7):799-802. PubMed ID: 17509945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of Autoimmune Hepatitis].
    Kim JK
    Korean J Gastroenterol; 2023 Feb; 81(2):72-85. PubMed ID: 36824035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.